Following Patients With Multiple Myeloma in West-Occitanie
Therapeutic and Support Oncologic Medical Care Evaluation in Patients With Multiple Myeloma in West-Occitanie Region. Factors Influencing Medical Care and Predictive and Prognostic Impact.
This study looks at how patients with multiple myeloma in the West-Occitanie region are treated and how their health changes over time to better understand their experiences and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse, West-Occitanie) |
| Trial ID | NCT04888039 on ClinicalTrials.gov |
What this trial studies
This observational study aims to describe the health care pathways of patients with multiple myeloma living in the West-Occitanie region. It will collect data on socio-demographic characteristics, comorbidities, and disease severity, tracking patients' responses to various therapies and their quality of life over time. The study will also assess progression-free survival, overall survival, and the occurrence of secondary malignancies or severe neuropathy during treatment. By analyzing this data, the study seeks to improve understanding of treatment outcomes and patient experiences.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with symptomatic multiple myeloma residing in the West-Occitanie region.
Not a fit: Patients who are opposed to participating in the research or are under legal protection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the quality of care and treatment strategies for patients with multiple myeloma.
How similar studies have performed: While there is limited real-life data on multiple myeloma, similar observational studies have shown promise in improving patient care pathways.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient living in the West-Occitanie region * Patient with a diagnosis of symptomatic multiple myeloma (Rajkumar et al, Lancet Oncology 2014) Exclusion Criteria: * Patient opposed to this research * Patient under legal protection
Where this trial is running
Toulouse, West-Occitanie
- IUCT-Oncopole - Toulouse University Hospital — Toulouse, West-Occitanie, France (Recruiting)
Study contacts
- Principal investigator: Aurore PERROT, MD — IUCT-Oncopole - Toulouse University Hospital
- Study coordinator: Aurore PERROT, MD
- Email: perrot.aurore@iuct-oncopole.fr
- Phone: +33 5 31 15 64 90
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.